Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,161 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07138716Recruiting
PET/CT scan for medullary thyroid carcinoma
This study tests a new imaging agent (68Ga-DOTA-CCK-FS) that helps doctors see medullary thyroid carcinoma (MTC) and other tumors with CCK-2 receptors using a PET/CT scan. It may help find or monitor these tumors more clearly.
Beijing, Beijing MunicipalityAges Any age - NCT07139418Recruiting
Studying lymph nodes around the stomach in cancer surgery
This trial studies the importance of checking lymph nodes in the fatty tissue around the stomach during stomach cancer surgery. It helps doctors understand if examining these specific areas can improve treatment decisions.
Hangzhou, ZhejiangAges 18–85 - NCT07140679RecruitingPhase 2
Immunotherapy after surgery for certain colon cancers
This trial tests whether the immunotherapy drug toripalimab can lower the risk of colon cancer coming back after surgery. It is for people with a specific genetic feature called mismatch repair deficiency (dMMR) in their tumor, and whose cancer was at a higher stage (stage IIB, IIC, or III).
Atlanta, GeorgiaAges 18 years+ - NCT07142213Recruiting
Studying a two-step liver surgery for liver cancer
This trial looks at a special two-step surgery called ALPPS for people with liver cancer that can't be removed in one operation. The first step helps the liver grow more healthy tissue, and then the second step removes the tumor. The goal is to understand how well this works and how the liver regenerates.
Beijing, Beijing MunicipalityAges 18–75 - NCT07145801RecruitingPhase 2
Y-90 treatment response for liver cancer
This trial tests how well a Y-90 radiation treatment works for liver cancer that hasn't been treated before. It uses ultrasound imaging to check the response.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07146646RecruitingPhase 2
Chemo combo for advanced bile duct cancer
This trial tests a combination of two chemotherapy drugs (trifluridine/tipiracil and oxaliplatin) for people with advanced or metastatic bile duct cancer (including gallbladder cancer) who have only had one prior treatment. The goal is to see if this combination can help control the cancer.
Cleveland, OhioAges 19 years+ - NCT07150624RecruitingPhase 4
Polyene phosphatidylcholine for liver injury after surgery
This trial tests whether a medicine called polyene phosphatidylcholine can help protect the liver from damage after surgery for liver cancer. It is for people who are having a specific type of keyhole surgery to remove part of the liver.
Hefei, AnhuiAges 18–70 - NCT07151040RecruitingPhase 1/Phase 2
Testing TH9619 for advanced solid tumors
This trial tests a new drug called TH9619 for people with advanced cancers of the colon, head and neck, lung, or stomach. It aims to see if the drug is safe and works against tumors that have already been treated with chemotherapy.
VillejuifAges 18 years+ - NCT07157969RecruitingPhase 2
Immunotherapy and anti-VEGF with or without local therapy for liver cancer
This trial tests a combination of immunotherapy (checkpoint inhibitors) and anti-VEGF therapy (which blocks blood vessel growth to tumors) with or without local treatments (like chemoembolization) for advanced liver cancer. It aims to see if the combination works better than current treatments.
BeijingAges 18 years+ - NCT07158021RecruitingPhase 2
Comparing two ovarian suppression drugs for breast cancer
This trial tests two hormone-blocking injections (leuprolide and goserelin) to suppress ovarian function in premenopausal women with breast cancer. It aims to see how well these drugs work when taken with standard hormone pills.
Ann Arbor, MichiganAges 18 years+ - NCT07160335RecruitingPhase 1
Testing a potential biosimilar for multiple resected solid tumors
This trial tests whether a new drug, HLX17, works as well as the approved drug Keytruda® in people whose solid tumors (like lung cancer, melanoma, or kidney cancer) have been fully removed by surgery. The goal is to see if the new drug can help prevent the cancer from coming back.
Glendale, CaliforniaAges 18–85 - NCT07164027RecruitingEarly Phase 1
Comparing a new PSMA scan to MRI for prostate cancer detection
This trial tests whether a new imaging agent (flotufolastat F 18 PET CT) can find prostate cancer better than MRI. If you have a suspicious spot on an MRI, this study may help doctors see if the new scan is more accurate.
Los Angeles, CaliforniaAges 18–90 - NCT07164313RecruitingPhase 1
ZW251 for advanced solid tumors
This trial is testing a new drug called ZW251 for people with advanced liver cancer (hepatocellular carcinoma), non-small cell lung cancer, or germ cell tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT07167329RecruitingPhase 2
Belzutifan for VHL syndrome: a real-world study
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
São Paulo, São PauloAges 14 years+ - NCT07171190Recruiting
Adding abdominal CT to standard lung cancer screening
This study adds an optional CT scan of the belly to the usual lung cancer screening in certain areas of England. It aims to see if this extra scan helps find more health issues early.
HullAges 55–70 - NCT07172386RecruitingPhase 2
Pre-surgery treatment for advanced kidney cancer
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07172802RecruitingPhase 1/Phase 2
Study of GI-108 for advanced solid tumors
This trial tests a new drug called GI-108, which is designed to help your immune system fight cancer. It is for people with advanced or metastatic solid tumors that have not responded to other treatments.
SeoulAges 18 years+ - NCT07178093Recruiting
Mushroom extract for liver cancer after TACE
This trial is testing if an extract from a medicinal mushroom (Antrodia cinnamomea) can help people with liver cancer who have had a treatment called TACE (chemoembolization). It looks at whether the mushroom extract can improve liver health and recovery after the procedure.
Taichung, TaiwanAges 20–80 - NCT07183319RecruitingPhase 2
ctDNA test in advanced bladder cancer
This trial studies how a blood test that looks for tumor DNA (ctDNA) can help guide treatment in people with advanced bladder cancer that cannot be removed by surgery or has spread. It aims to see if the test results can help doctors choose the best therapy.
Oklahoma City, OklahomaAges 18 years+ - NCT07185165RecruitingPhase 2
PET Scan for Prostate Cancer Recurrence After Focal Therapy
This study uses a special PET/CT scan (Flotufolastat F 18) to look for leftover or returning prostate cancer after you've had a targeted treatment called focal therapy. The goal is to see if the scan can help find cancer that might need further treatment.
Los Angeles, CaliforniaAges 18–90 - NCT07186621RecruitingPhase 3
Testing immunotherapy or chemoembolization after liver cancer surgery
This trial compares two treatments after liver cancer surgery to see which better prevents the cancer from coming back. You may be eligible if your surgery had a narrow margin and you have certain risk factors, like a tumor over 5 cm or high AFP levels.
BeijingAges 18–80 - NCT07186699Recruiting
Understanding lung cancer in people with past alcohol or drug use
This study looks at the experiences of people with lung cancer (NSCLC) who also have a history of alcohol or drug use. It aims to help doctors better understand and support patients facing both challenges.
Los Angeles, CaliforniaAges 18 years+ - NCT07188584RecruitingPhase 3
Smaller radiation vs. standard after chemo-immunotherapy for advanced nasopharyngeal cancer
This trial tests whether a smaller radiation treatment area is as effective as the usual larger one for people whose metastatic nasopharyngeal cancer has responded well to first-line chemotherapy plus immunotherapy. It aims to reduce side effects while keeping the cancer under control.
ZhuhaiAges 18–70 - NCT07192068RecruitingPhase 2
Zanidatamab for HER2-altered solid tumors
This trial tests a drug called zanidatamab in people with certain cancers (endometrial, colorectal, head & neck, non-small cell lung, or sarcoma) that have a specific change in the HER2 gene. It's for those whose cancer has spread or can't be removed and who have tried at least one prior treatment.
AngersAges 18 years+
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,161 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.